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already built rather than starting anew. The simplicity of naming
resistance gene determinants will not only help in maintaining the
interest of early-career academics and clinicians in understanding
antimicrobial resistance determinants, but also encourage more
research into the evolution of resistance genes.
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Sir,
Schena et al.1 recently reported a BACTECTM MGITTM-based proto-
col for delamanid drug susceptibility testing (DST). While we
appreciate the authors’ carefully and thoroughly executed work,
we would like to take the opportunity to briefly comment.
Schena et al.1 criticize a previously established protocol as
follows: ‘Recently, Keller et al.2 proposed a DST protocol for dela-
manid in the MGIT, but the study had two major weaknesses: (i)
the sample size of strains (25 M. tuberculosis isolates) was rather
small; and (ii) the authors used delamanid derived from mortared
pills instead of pure substance, as recommended by WHO.3’ The
recommendation Schena et al.1 refer to is not an official state-
ment by the WHO, but a publication by Diacon et al.3 As pointed
out by Keller et al.,2 it was impossible to obtain delamanid from
the producer, Otsuka, without unacceptable binding conditions.
Keller et al.2 readily addressed the limitations of their study:
‘Further studies evaluating in vitro laboratory drug MICs using
pure compounds and PK/PD and clinical data from a large number
of drug-susceptible and drug-resistant strains are required to
define clinical breakpoints.’ Most notably, the epidemiological cut-
off determined by Schena et al.1 (0.06 mg/L) is virtually identical
to the epidemiological cut-off determined by Keller et al.2
(0.04 mg/L). The small difference likely reflects the different
2-fold dilution series.
Experiments conducted in our laboratory indicate that the use
of pure delamanid may be problematic, as the drug appears
somewhat unstable during incubation in growth medium. Thus,
we are wondering whether the substance Schena et al.1 received
from Otsuka for their study is indeed pure delamanid, as stated in
the Materials and methods section, or whether a stabilizer had
been added by the producer.
We are surprised that Schena et al.1 are not concerned by the
drug company’s policy of denying access to delamanid without
extensive binding conditions for use and data publication. This is
a policy not previously seen for antimicrobials entering the mar-
ket, as antibiotic susceptibility testing (AST) needs to be estab-
lished and verified independently by expert laboratories. Rather,
Schena et al.1 criticize our work, which we did to avoid the restric-
tions imposed by Otsuka and to develop expert AST independently
of company interests.
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